Tiziana's Foralumab Hits Goals in MS Phase 2 Trial

Tiziana Life Sciences announced positive results from a phase 2 trial of Foralumab in secondary progressive multiple sclerosis. The trial met primary endpoints, showing reduced neuroinflammation and safety. Secondary endpoints, including fatigue and EDSS scores, also showed statistical significance. The company plans to advance the 50 microgram dose in future studies.

Original reporting
Published Nov 16, 2026, 10:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 10:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tiziana's Foralumab Hits Goals in MS Phase 2 Trial — source image
Decision brief

The 30-second read

Low
01

Why it matters

The article claims the trial met the primary endpoint of reduced neuroinflammation on PET and also reports statistical significance in secondary endpoints (EDSS and fatigue), which would be a meaningful clinical development signal if confirmed in a full dataset and filing.

02

Market read

If validated, the Phase 2 readout is a development catalyst for the company’s MS pipeline and could shift expectations for subsequent trials and partnering discussions.

03

What to watch

The transcript excerpt omits key trial specifics (n per arm, adverse events, imaging quantification method, and whether results are clinically meaningful beyond PET and fatigue scores).

Relevance 6/10Novelty 5/10Timing: data readout described as completed last week, discussed in a dated presentation

Background

Tiziana Life Sciences CEO describes a Phase 2 placebo-controlled, double-blind trial of furalumab (intranasal, CD3-binding fully human monoclonal antibody) in secondary progressive multiple sclerosis, with PET imaging of activated microglia and fatigue/EDSS as secondary endpoints.

Market effects

Positive Phase 2 readout in SPMS could modestly improve sentiment toward neuroinflammation and intranasal biologic approaches in MS R&D.

No clear regional market catalyst beyond biotech sentiment.

MS trial outcomes can influence global biotech risk appetite for CNS immunology programs.

Counterpoint

Statistical significance is described as borderline (p=0.168 reported), and the article excerpt does not provide effect size, durability, or full safety details.

Key entities

  • Tiziana Life Sciences

    Subject of the presentation, reporting Phase 2 SPMS trial results for furalumab.

  • Furalumab

    Intranasal fully human monoclonal antibody binding CD3, intended to induce Tregs and suppress activated microglia.

  • Secondary progressive multiple sclerosis (SPMS)

    Patient cohort described as having no specifically approved effective therapy, per the speaker.

Related articles

$TLSAMedAI 8/10

Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London

Tiziana Life Sciences (TLSA) will present at the Jefferies Healthcare Conference in London on November 18, 2026. The company will discuss its Phase 2a INFORM-MS trial results for intranasal foralumab in non-active secondary progressive multiple sclerosis, which met primary endpoints and showed clinical improvements. Management will also be available for one-on-one meetings.

$TLSAHighAI 8/10

Tiziana Life Sciences Ltd.: Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Scler

Tiziana Life Sciences (TLSA) reported positive Phase 2a INFORM-MS trial results for its lead drug, intranasal foralumab, in treating non-active secondary progressive multiple sclerosis (na-SPMS). Key findings include statistically significant reductions in microglial activation and improvements in fatigue. The results align with longer-term data from the company's expanded access program, showing EDSS stabilization and improvement.

$TLSAHighAI 9/10

A nasal drug for MS reduced a brain inflammation measure in a 12-week trial

Tiziana Life Sciences (TLSA) reported positive Phase 2a trial results for its intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS). The trial met primary endpoints, showing a statistically significant reduction in microglial activation and clinically meaningful fatigue improvements. The company will host a conference call to discuss the results, with key opinion leaders presenting the data. TLSA plans to engage with the FDA for next steps in development.